Literature DB >> 22438541

Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses.

Yo Han Jang1, Young Ho Byun, Yoon Jae Lee, Yun Ha Lee, Kwang-Hee Lee, Baik Lin Seong.   

Abstract

The rapid transmission of the pandemic 2009 H1N1 influenza virus (pH1N1) among humans has raised the concern of a potential emergence of reassortment between pH1N1 and highly pathogenic influenza strains, especially the avian H5N1 influenza virus. Here, we report that the cold-adapted pH1N1 live attenuated vaccine (CApH1N1) elicits cross-reactive immunity to seasonal and H5 influenza A viruses in the mouse model. Immunization with CApH1N1 induced both systemic and mucosal antibodies with broad reactivity to seasonal and H5 strains, including HAPI H5N1 and the avian H5N2 virus, providing complete protection against heterologous and heterosubtypic lethal challenges. Our results not only accentuate the merit of using live attenuated influenza virus vaccines in view of cross-reactivity but also represent the potential of CApH1N1 live vaccine for mitigating the clinical severity of infections that arise from reassortments between pH1N1 and highly pathogenic H5 subtype viruses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22438541      PMCID: PMC3347274          DOI: 10.1128/JVI.07149-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.

Authors:  Shin-ichi Tamura; Takeshi Tanimoto; Takeshi Kurata
Journal:  Jpn J Infect Dis       Date:  2005-08       Impact factor: 1.362

2.  Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.

Authors:  Kwang-Hee Lee; Sang-Uk Seo; Jae-Min Song; Chung-Min Lee; Hyun-Ah Kim; Baik L Seong
Journal:  Vaccine       Date:  2005-11-08       Impact factor: 3.641

3.  Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection.

Authors:  M Gocník; T Fislová; T Sládková; V Mucha; F Kostolanský; E Varecková
Journal:  J Gen Virol       Date:  2007-03       Impact factor: 3.891

4.  Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine.

Authors:  G J Gorse; M J Campbell; E E Otto; D C Powers; G W Chambers; F K Newman
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

5.  A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.

Authors:  K M Edwards; W D Dupont; M K Westrich; W D Plummer; P S Palmer; P F Wright
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

6.  Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells.

Authors:  K A Benton; J A Misplon; C Y Lo; R R Brutkiewicz; S A Prasad; S L Epstein
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

7.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.

Authors:  R B Belshe; W C Gruber; P M Mendelman; H B Mehta; K Mahmood; K Reisinger; J Treanor; K Zangwill; F G Hayden; D I Bernstein; K Kotloff; J King; P A Piedra; S L Block; L Yan; M Wolff
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

8.  Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses.

Authors:  G J Gorse; R B Belshe
Journal:  Scand J Infect Dis       Date:  1991

9.  The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets.

Authors:  Zhongying Chen; Lomi Kim; Kanta Subbarao; Hong Jin
Journal:  Vaccine       Date:  2012-02-11       Impact factor: 3.641

10.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

View more
  20 in total

Review 1.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

2.  Coxsackievirus B3 engineered to contain microRNA targets for muscle-specific microRNAs displays attenuated cardiotropic virulence in mice.

Authors:  Feng He; Hailan Yao; Jianmin Wang; Zonghui Xiao; Le Xin; Zhuo Liu; Xiaolin Ma; Juan Sun; Qi Jin; Zhewei Liu
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

Review 3.  Cross-protective immune responses elicited by live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

4.  Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the Flumist vaccine.

Authors:  Bram Slütter; Lecia L Pewe; Peter Lauer; John T Harty
Journal:  J Immunol       Date:  2013-03-06       Impact factor: 5.422

5.  Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.

Authors:  Irina Isakova-Sivak; Li-Mei Chen; Melissa Bourgeois; Yumiko Matsuoka; J Theo M Voeten; Jacco G M Heldens; Han van den Bosch; Alexander Klimov; Larisa Rudenko; Nancy J Cox; Ruben O Donis
Journal:  Clin Vaccine Immunol       Date:  2014-03-19

Review 6.  Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?

Authors:  Mattia Tiboni; Luca Casettari; Lisbeth Illum
Journal:  Int J Pharm       Date:  2021-05-06       Impact factor: 6.510

7.  Toward a universal influenza vaccine: from the perspective of protective efficacy.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

8.  Principles underlying rational design of live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik-Lin Seong
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

Review 9.  Options and obstacles for designing a universal influenza vaccine.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Viruses       Date:  2014-08-18       Impact factor: 5.048

10.  Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.

Authors:  Irina Isakova-Sivak; Jørgen de Jonge; Tatiana Smolonogina; Andrey Rekstin; Geert van Amerongen; Harry van Dijken; Justin Mouthaan; Paul Roholl; Victoria Kuznetsova; Elena Doroshenko; Vadim Tsvetnitsky; Larisa Rudenko
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.